Celgene's psoriasis drug apremilast performs well in trial

03/4/2013 | Reuters

More psoriasis patients who took Celgene's experimental drug apremilast experienced improvements in symptoms compared with patients who took a placebo, a late-stage trial found. Celgene plans to submit the drug for FDA approval this year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park